Literature DB >> 1730524

An immunohistochemical survey of pS2 expression in human epithelial cancers.

Y A Luqmani1, G Ryall, S Shousha, R C Coombes.   

Abstract

The oestrogen-inducible pS2 protein isolated from human breast-cancer cells appears to have prognostic significance in breast-cancer patients. Using both monoclonal and polyclonal pS2 anti-sera, we have carried out an immunocytochemical survey of 9 epithelial cancers. Some degree of specific tumour staining was observed in 4 tissues, the extent varying greatly between specimens. Most (11/13) of the colorectal cancers showed immunoreactivity, as did 4/5 pancreatic carcinomas. In some of these cases, patchy staining was also observed in adjacent non-tumour cells. Two bronchio-alveolar carcinomas showed positivity, but 5 poorly differentiated adenocarcinomas of the lung did not. In the ovary, staining was observed in 3/3 mucinous cystadenocarcinomas but only in 1/8 of the serous type. No reactivity was seen in specimens of salivary gland, kidney, liver, prostate or uterus. This pilot study indicates that pS2 may be a useful marker of adenocarcinomas in human neoplasms apart from those in the breast, and suggests that more extensive surveys might be worthwhile.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730524     DOI: 10.1002/ijc.2910500222

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  Growth factors in the gastrointestinal tract.

Authors:  N R Lemoine; H Y Leung; W J Gullick
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

Review 2.  Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database.

Authors:  Koh Miura; Kazuyuki Ishida; Wataru Fujibuchi; Akihiro Ito; Hitoshi Niikura; Hitoshi Ogawa; Iwao Sasaki
Journal:  Surg Today       Date:  2012-03-23       Impact factor: 2.549

3.  Trefoil factor 1 acts to suppress senescence induced by oncogene activation during the cellular transformation process.

Authors:  Daniel R Radiloff; Timothy P Wakeman; Junjie Feng; Stephen Schilling; Edward Seto; Xiao-Fan Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-30       Impact factor: 11.205

4.  A second trefoil protein, ITF/hP1.B, is transcribed in human breast cancer.

Authors:  B Theisinger; G Seitz; S Dooley; C Welter
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Differential expression of human spasmolytic polypeptide (trefoil factor family-2) in pancreatic carcinomas, ampullary carcinomas, and mucin-producing tumors of the pancreas.

Authors:  G Ohshio; H Suwa; Y Kawaguchi; M Imamura; Y Yamaoka; H Yamabe; M Matsumoto; H Yoshioka; Y Hashimoto; H Takeda
Journal:  Dig Dis Sci       Date:  2000-04       Impact factor: 3.199

6.  Expression of pS2 protein in breast cancer.

Authors:  G Crombach; A Ingenhorst; U J Göhring; A Scharl; W Neuhaus; V Möbus; H J Schaeffer
Journal:  Arch Gynecol Obstet       Date:  1993       Impact factor: 2.344

7.  Expression of pS2 in prostate cancer correlates with grade and Chromogranin A expression but not with stage.

Authors:  M Hammad Ather; Farhat Abbas; Nuzhat Faruqui; M Israr; Shahid Pervez
Journal:  BMC Urol       Date:  2004-12-10       Impact factor: 2.264

8.  Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast.

Authors:  Y A Luqmani; T Campbell; S Soomro; S Shousha; M C Rio; R C Coombes
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.